Short answer
Guardant Health, Inc. (GH) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $361M (up 36.1% year over year) with net income of −$124M.
Q3 2026 key financials · XBRL
- Revenue
- $361M
- +36.1% YoY · +7.8% QoQ
- Net income
- −$124M
- −34.1% YoY · −3.5% QoQ
- Operating margin
- -36.8%
- EPS (diluted)
- −$0.92
- −22.7% YoY · −1.1% QoQ
Source: XBRL data from the Guardant Health, Inc. (GH) Q3 2026 10-Q on SEC EDGAR. USD.
Guardant Health, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $361.0M, up 36% YoY from $265.2M
- Operating loss $132.8M vs $99.0M YoY, operating margin (36.8%) vs (37.3%)
- Best segment Screening: $67.6M, up 180% YoY; worst growth Biopharma and data: $59.0M, up 8%
- Cash, equivalents and restricted cash $1.1B; nine-month operating cash outflow $147.1M vs $158.4M
- Outlook: additional operating losses expected; liquidity sufficient for more than 12 months, reimbursement variability remains a headwind
Risk Factors
- New cybersecurity risk triggered by unauthorized portal access, with certain patient records potentially accessed
- AI-enabled attacks increasing speed, scale and sophistication of exploitation
- Regulatory exposure from compromised patient data, including investigations, enforcement actions and penalties
- Operational disruption risk across testing, reporting, billing and reimbursement systems
- Third-party service-provider vulnerabilities potentially compromising Guardant information systems
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Guardant Health, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.